Daily coverage of equity markets, sectors, and major indices.
In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.
30,184 total articles
Generate Biomedicines, Inc. filed to raise up to $425 million in an initial public offering on the Nasdaq under the symbol GENB. The company plans to offer 25 million shares at an expected price of $15.00 to $17.00 per share and has granted underwriters an option for an additional 3.75 million shares. Its lead candidate, GB-0895, entered Phase 3 do…
Novo Nordisk’s experimental obesity drug CagriSema underperformed Eli Lilly’s Zepbound in a direct comparison, prompting analysts to question Novo’s path to regain its early lead in the obesity drug market. Industry strategists say the trial result amplifies commercial uncertainty and could push investor attention to potential M&A moves to shore up…
Jefferies downgraded Deere & Co to Underperform, arguing the stock's rally has priced in a full recovery in the agriculture cycle and elevated multiples. The broker set a $550 target tied to a 15x multiple on what it expects to be peak earnings in 2029, and highlighted weakening farmer incomes, falling high-horsepower equipment sales, and persisten…
Bank of America defended Blue Owl, saying market misinformation and elevated uncertainty have depressed the stock and created an attractive entry point. The bank set a $24 price target - more than a 100% total-return upside from current levels - based on a 25-times multiple on its 2028 distributable earnings estimate after adjusting for stock-based…
ASML researchers report a technical advance that raises the power of the extreme ultraviolet (EUV) light source in its chip-printing machines from 600 watts to 1,000 watts. The company says the development could enable individual EUV systems to produce roughly 50% more chips by the end of the decade by increasing wafer throughput to about 330 wafer…
Shares of Allurion Technologies jumped 40% after U.S. Food and Drug Administration approval of the Allurion Gastric Balloon System, which includes the ingestible Allurion Smart Capsule. The approval covers treatment for adults with a body mass index of 30 to 40 kg/m2, potentially addressing roughly 80 million Americans in that range, according to t…
Bank of America analysts say the Supreme Court's decision to invalidate the IEEPA-based tariffs has delivered a notable positive shock to portions of the small- and mid-cap e-commerce universe. Shares in the group rallied after the ruling but pared gains when a new global tariff under Section 122 was announced. Within the sector, Etsy is singled ou…
Summary: Our Bond, Inc. (NASDAQ:OBAI) said it signed a phase 1 commercial agreement worth approximately $250,000 with one of the world’s five largest pharmaceutical companies. The deal will roll out Bond’s AI-powered personal security platform to about 5,000 of the pharmaceutical firm’s 100,000 U.S. employees, establishing a $250,000 annual recurri…
TOP Ships Inc. (NASDAQ:TOPS) said it will acquire nine special purpose companies that hold shipbuilding contracts for ECO MR product/chemical tankers, in a deal that carries a potential gross revenue backlog of about $679 million. The transaction, with an entity affiliated with the company's CEO as seller, includes secured time charter employment s…
VenHub Global's stock rose 20% Monday morning after the company unveiled self-diagnostic systems across its autonomous store robotics. The upgrade includes component-level monitoring and a predictive maintenance tool that alerts operators and VenHub's service team when motors or sensors approach the need for servicing or replacement. The changes ar…
Shares of Reliance Global Group Inc (NASDAQ: EZRA) surged in premarket trading after the company completed the acquisition of Enquantum Ltd., a developer of hardware-accelerated, NIST-aligned post-quantum cryptography. The transaction is structured as a milestone-driven program intended to raise Reliance's stake to a 51% fully diluted controlling i…
Dominion Energy raised its five-year capital spending plan as it responds to growing electricity demand from large data centers, but projected 2026 operating earnings that sit below analysts' consensus. The company reported a modest beat on fourth-quarter adjusted earnings, while operating expenses climbed nearly 11%, and its shares slipped in prem…
United Homes Group (NASDAQ:UHG) saw its stock drop 49.6% in premarket trading Monday following announcement that Stanley Martin Homes will acquire the company in an all-cash deal. The transaction values United Homes at an enterprise value of about $221 million and offers shareholders $1.18 per share, a significant discount to the company’s most rec…
Enhabit Inc. agreed to be acquired by private equity firm Kinderhook Industries in an all-cash transaction valued at roughly $1.1 billion. The deal, unanimously approved by Enhabit’s board, will pay stockholders $13.80 per share and is expected to close in the second quarter of 2026 subject to customary approvals. Following the announcement, Enhabi…
U.S. equity benchmarks closed higher on Friday after the Supreme Court curtailed much of President Trump's tariff program, a move that could ease cost pressures for businesses. The S&P 500, Nasdaq and Dow all posted gains for the day and week, while attention shifts to Nvidia's upcoming earnings and a docket of economic reports due in the coming da…
Psyence Biomedical Ltd. (NASDAQ:PBM) said it will acquire 2,900 shares of Psyence Labs Ltd. through a share-for-share exchange after Psyence Labs exercised a previously disclosed put option. The Labs shares are valued at $5 million using a per-share fair market valuation of $1,724. In return, Psyence Biomedical will issue 1,146,159 common shares to…
MoonLake Immunotherapeutics saw its stock climb in premarket trading after disclosing topline results from the Phase 2 S-OLARIS study of sonelokimab in axial spondyloarthritis (axSpA). The data showed high rates of clinical response at Week 12, corroborated by PET and MRI imaging, while the safety profile remained consistent with earlier studies. T…
Gossamer Bio's stock plunged 80% on Monday after its inhaled investigational therapy seralutinib did not meet the primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension (PAH). The trial showed a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of 13.3 meters at Week 24 with a p-value of 0.0320, missing the …
President Trump announced an across-the-board 15% tariff under Section 122 following a Supreme Court decision that invalidated his prior use of emergency powers to impose tailored levies. Wolfe Research analysts Tobin Marcus and Chutong Zhu reviewed the major open questions this development leaves in its wake, including how much the 15% rate narrow…
Armata Pharmaceuticals saw premarket gains after the U.S. Food and Drug Administration awarded Qualified Infectious Disease Product (QIDP) designation to AP-SA02, its multi-phage intravenous candidate for complicated Staphylococcus aureus bacteremia. The designation confers regulatory incentives, including five years of market exclusivity and eligi…
Rothschild Redburn has downgraded Airbus Group SE to Neutral and reduced its price target to €200 from €230, citing operational setbacks on the A320neo and A350 programmes that outweigh robust market demand. The brokerage highlights quality issues, engine supply shortages and broader supply-chain limits that could delay production ramp-ups and weig…
Eli Lilly premarket shares rose after Novo Nordisk reported its experimental obesity drug CagriSema did not meet the trial's primary endpoint of non-inferiority to Eli Lilly's Tirzepatide. The trial showed a 23% weight reduction for CagriSema versus 25.5% for Tirzepatide over 84 weeks. Novo Nordisk will test a higher dose in the second half of 2026…
Vertical Aerospace (NYSE: EVTL) shares fell 2.7% in premarket trading after Raymond James downgraded the stock from Market Perform to Underperform. Analyst Savanthi Syth pointed to concerns about the company’s financial runway, competitive pressure from rivals, and potential talent losses, while noting the company is seeking an industrial partner t…
Acadia Pharmaceuticals shares rose 1.9% in premarket trading after Mizuho analyst Uy Ear upgraded the stock from Neutral to Outperform and lifted the price target to $35.00 from $29.00. The upgrade reflects a view that remlifanserin (ACP-204), Acadia’s Phase 2 candidate in the RADIANT trial for Alzheimer’s disease psychosis, is undervalued, and tha…
Investor Ed Garden's firm has accumulated a meaningful stake in Fortune Brands Innovations (FBIN) and is pressing for leadership and board changes, including efforts to replace the incoming CEO. The move follows a recent CEO departure, weak quarterly results and a rapid announcement of a successor. Fortune Brands' shares moved higher in premarket t…
